Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series

Non-vitamin K antagonist oral anticoagulants’ interindividual trough concentration variability affects efficacy and safety, especially in bleeding events. Rivaroxaban is metabolised via CYP3A4/5-, CYP2J2-, and CYP-independent mechanisms and is a substrate of two transporter proteins: ABCB1 (MDR1, P-glycoprotein) and ABCG2 (BCRP; breast-cancer-resistance protein). The polymorphisms of these genes may possibly affect the pharmacokinetics of rivaroxaban and, consequently, its safety profile. Rivaroxaban variability may be associated with age, liver and kidney function, concomitant illness and therapy, and pharmacogenetic predisposition. This case series is the first, to our knowledge, that presents multiple risk factors for rivaroxaban-related bleeding (RRB) including age, renal function, concomitant diseases, concomitant treatment, and pharmacogenetic data. It presents patients with RRB, along with their complete clinical and pharmacogenetic data, as well as an evaluation of possible risk factors for RRB. Thirteen patients were carriers of ABCB1, ABCG2, CYP2J2, and/or CYP3A4/5 gene polymorphisms. Possible drug–drug interactions with increased bleeding risk were identified in nine patients. Six patients had eGFR <60 mL/min/1.73 m2. Our data suggest a possible role of multiple factors and their interactions in predicting RRB; however, they also indicate the need for further comprehensive multidisciplinary research to enable safer use of this product based on a personalised approach.

[1]  N. Limdi,et al.  Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients , 2022, Frontiers in Pharmacology.

[2]  A. Corsini,et al.  Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice , 2022, Pharmaceutics.

[3]  M. Niemi,et al.  Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users , 2021, Clinical pharmacology and therapeutics.

[4]  I. Cascorbi,et al.  ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding? , 2021, Expert opinion on drug metabolism & toxicology.

[5]  M. Ajmal,et al.  Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review , 2021, Cardiovascular therapeutics.

[6]  Huijun Sun,et al.  Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant , 2021, Cardiovascular Drugs and Therapy.

[7]  F. Lamoureux,et al.  Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review , 2021, Journal of personalized medicine.

[8]  Takahiko Kinjo,et al.  Impact of gene polymorphisms in drug‐metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation , 2020, Basic & clinical pharmacology & toxicology.

[9]  E. Stecker,et al.  Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges , 2020, Journal of the American Heart Association.

[10]  William R Arnold,et al.  CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design. , 2020, Pharmacology & therapeutics.

[11]  D. Garcia,et al.  Should we monitor the direct oral anticoagulants? , 2020, Journal of Thrombosis and Thrombolysis.

[12]  Nadine Shehab,et al.  Emergency Visits for Oral Anticoagulant Bleeding , 2019, Journal of General Internal Medicine.

[13]  P. Bochkov,et al.  Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery , 2019, High Blood Pressure & Cardiovascular Prevention.

[14]  Rivaroxaban , 2019, Reactions Weekly.

[15]  J. Zolnerciks,et al.  ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors , 2019, Expert opinion on drug metabolism & toxicology.

[16]  Q. Xiang,et al.  Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysis. , 2018, Current pharmaceutical design.

[17]  V. Stepanov,et al.  A comprehensive study revealed SNP–SNP interactions and a sex-dependent relationship between polymorphisms of the CYP2J2 gene and hypertension risk , 2018, Hypertension Research.

[18]  J. Dogné,et al.  Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study , 2018, Thrombosis Journal.

[19]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[20]  Yitian Zhou,et al.  Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing Projects , 2017, Clinical pharmacology and therapeutics.

[21]  M. Loriot,et al.  Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin , 2017, Journal of thrombosis and haemostasis : JTH.

[22]  Y. Daali,et al.  Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect , 2016, Front. Pharmacol..

[23]  S. Zhai,et al.  Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis , 2015, PloS one.

[24]  I. Cascorbi,et al.  Functional Gene Variants of CYP3A4 , 2014, Clinical pharmacology and therapeutics.

[25]  W. Mueck,et al.  Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban , 2013, Clinical Pharmacokinetics.

[26]  V. Haufroid,et al.  CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. , 2013, Pharmacogenomics.

[27]  Chapter 1: Definition and classification of CKD , 2012, Kidney International Supplements.

[28]  V. Haufroid,et al.  A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. , 2011, Clinical chemistry.

[29]  W. Sadee,et al.  Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs , 2011, The Pharmacogenomics Journal.

[30]  Russ B Altman,et al.  PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2. , 2011, Pharmacogenetics and genomics.

[31]  Francesco Pignatti,et al.  The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use. , 2010, The oncologist.

[32]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[33]  T. Ishikawa,et al.  Major SNP (Q141K) Variant of Human ABC Transporter ABCG2 Undergoes Lysosomal and Proteasomal Degradations , 2009, Pharmaceutical Research.

[34]  M. Pirmohamed,et al.  ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research , 2007, The Pharmacogenomics Journal.

[35]  M. Shimizu,et al.  Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[36]  Y. Sugiyama,et al.  Functional Analysis of SNPs Variants of BCRP/ABCG2 , 2004, Pharmaceutical Research.

[37]  M. Fromm,et al.  Importance of P-glycoprotein at blood-tissue barriers. , 2004, Trends in pharmacological sciences.

[38]  V. Smirnov,et al.  CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. , 2018, Genetic testing and molecular biomarkers.

[39]  J. Stockman,et al.  A New Equation to Estimate Glomerular Filtration Rate , 2011 .